138383-07-0
| 中文名称 | 138383-07-0 |
|---|---|
| 中文同义词 | 化合物 T12993;化合物 SQ-31765 |
| 英文名称 | SQ-31765 |
| 英文同义词 | 2H-1-Benzazepin-2-one, 3-(acetyloxy)-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-6-(trifluoromethyl)-, (3R,4S)-;SQ31765,SQ 31765 |
| CAS号 | 138383-07-0 |
| 分子式 | C24H27F3N2O4 |
| 分子量 | 464.48 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 138383-07-0.mol |
| 结构式 |  |
138383-07-0 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | 溶于二甲基亚砜 |
Calcium channel
SQ-31765 (SQ 31,765) can reduce the severity of ischemia in a manner which is independent of changes in myocardial blood flow or hemodynamic alterations. Anesthetized dogs are given saline (n=6), SQ-31765 (n=6; 0.2 mg/kg) or SQ 32,189 (n=6; 0.2 mg/kg) i.v. 10 min before ischemia. The effect on pacing-induced ST-segment elevation (pacing+left anterior descending coronary artery stenosis) and myocardial blood flow are determined. SQ-31765 reduces ST-elevation (P<0.05) compared to saline at 10, 40 and 70 min after infusion (5.9±1.4 and 12.0±1.4 mV, respectively, at 70 min). Left anterior descending coronary artery stenosis during atrial pacing resulted in a significant reduction in subendocardial flow in all groups before drug infusion (41±7, 44±7 and 35±9 mL/min/100 g for saline, SQ-31765 and SQ 32,189, respectively).